SCHEMBL1979793

SCHEMBL1979793

Nc1c(O)ccc2c1Cc1ccccc1O2

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.52
MAOB P27338 2/20 0.52
MAPKAPK2 P49137 8/20 0.51
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GAA P10253 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ACSL1 P33121 1/20 0.34
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7970202 0.83 MAOA (0.55) MAOAMAOBMAPKAPK2NPC1LMNA
SCHEMBL1461767 0.83 MAPKAPK2 (0.57) MAOAMAOBMAPKAPK2NPC1LMNA
SCHEMBL1979796 0.80 MAOA (0.52) MAOAMAOBMAPKAPK2NPC1LMNA
SCHEMBL1980248 0.79 MAOA (0.59) MAOAMAOBMAPKAPK2NPC1LMNA
Bromide SCHEMBL6129306 0.77 MAOA (0.57) MAOAMAOBMAPKAPK2NPC1LMNA
SCHEMBL88260 0.75 MAOA (0.59) MAOAMAOBMAPKAPK2NPC1LMNA
SCHEMBL31470407 0.75 MAOA (0.59) MAOAMAOBMAPKAPK2NPC1LMNA
SCHEMBL29453995 0.74 MAOA (0.64) MAOAMAOBMAPKAPK2NPC1LMNA
Hydrochloric Acid SCHEMBL28586545 0.74 MAOA (0.57) MAOAMAOBMAPKAPK2NPC1LMNA
SCHEMBL6667007 0.72 MAOA (0.46) MAOAMAOBMAPKAPK2NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160354533-A1 ADSORBING PATHOGEN-INACTIVATING COMPOUNDS WITH POROUS PARTICLES IMMOBILIZED IN A MATRIX CERUS CORPORATION (US) 2016-12-08 US disclosed
US-9259525-B2 Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix CERUS CORPORATION (US) 2016-02-16 US disclosed
EP-2358814-B1 PLASTICIZER FOR THERMOPLASTIC POLYMER MATERIALS AVENT INC (US) 2015-07-29 EP disclosed
EP-1508345-B1 System and method for the reduction of small organic compounds from blood products CERUS CORP (US) 2013-09-25 EP disclosed
US-8518315-B2 Plasticizer for thermoplastic materials KIMBERLY-CLARK WORLDWIDE, INC. (US) 2013-08-27 US disclosed
EP-2358814-A2 PLASTICIZER FOR THERMOPLASTIC POLYMER MATERIALS Kimberly-Clark Worldwide, Inc. (US) 2011-08-24 EP disclosed
US-20110143621-A1 PLASTICIZER FOR THERMOPLASTIC POLYMER MATERIALS AVANOS MEDICAL SALES, LLC 2011-06-16 US disclosed
WO-2010070524-A2 XANTHENE-BASED PLASTICIZER OF RESINS AND POLYMERS KIMBERLY-CLARK WORLDWIDE, INC. (US) 2010-06-24 WO disclosed
US-20100160484-A1 XANTHENE-BASED PLASTICIZER OF RESINS AND POLYMERS AVANOS MEDICAL SALES, LLC 2010-06-24 US disclosed
US-20100159769-A1 PLASTICIZER FOR THERMOPLASTIC MATERIALS AVANOS MEDICAL SALES, LLC 2010-06-24 US disclosed
EP-1044066-A1 BATCH DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS CONTAINING CELLS AND METHODS OF USE Cerus Corporation (US) 2000-10-18 EP disclosed
CN-1248178-A Method and device for reducing small organic molecules in blood products CERUS CORP (US) 2000-03-22 CN disclosed
EP-0954374-A1 METHODS AND DEVICES FOR THE REDUCTION OF SMALL ORGANIC COMPOUNDS FROM BLOOD PRODUCTS Cerus Corporation (US) 1999-11-10 EP disclosed
WO-1999034914-A1 BATCH DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS CONTAINING CELLS AND METHODS OF USE CERUS CORPORATION (US) 1999-07-15 WO disclosed
WO-1999034915-A1 FLOW DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS AND METHODS OF USE CERUS CORPORATION (US) 1999-07-15 WO disclosed
WO-1998030327-A1 METHODS AND DEVICES FOR THE REDUCTION OF SMALL ORGANIC COMPOUNDS FROM BLOOD PRODUCTS CERUS CORPORATION (US) 1998-07-16 WO disclosed
EP-0471794-B1 ANTIVIRAL THERAPY USING THIAZINE AND XANTHENE DYES OKLAHOMA MED RES FOUND (US) 1996-10-02 EP disclosed
EP-0471794-A4 ANTIVIRAL THERAPY USING THIAZINE AND XANTHENE DYES 1992-05-06 EP disclosed
EP-0471794-A1 ANTIVIRAL THERAPY USING THIAZINE AND XANTHENE DYES. OKLAHOMA MED RES FOUND (US) 1992-02-26 EP disclosed
WO-1990013296-A1 ANTIVIRAL THERAPY USING THIAZINE AND XANTHENE DYES OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 1990-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160484-A1 XANTHENE-BASED PLASTICIZER OF RESINS AND POLYMERS SMARCA2, SMARCA1, MYB MAOA 1730/4885MAOB 2569/4885MAPKAPK2 4256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.